# US 2013/0273576 A1 · Reagents for reducing leukocyte interference in immunoassays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0273576 A1
- Document ID: US20130273576A1
- Status: Published application
- Kind: A1
- Application number: 13/862,632
- Filed: 2013-04-15
- Published: 2013-10-17
- Earliest claimed: 2010-04-30
- Assignees: Abbott Point of Care Inc.
- Applicants: Abbott Point of Care Inc.
- Inventors: John Lewis Emerson Campbell; Graham Davis; John Emegbero Omakor; Adam Roger Moss; Ganesh Guhados
- Web page: https://patentgrep.com/patent/US20130273576A1

## CPC

- G01N 33/54393: {Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding}
- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- G01N 33/5375: {by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 2333/475: Assays involving growth factors
- Y10T 436/25125: Digestion or removing interfering materials
- Y10T 436/25375: Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors.

## Claims

### Claim 1

A method of performing an immunoassay for a target analyte in a blood sample comprising:
contacting a blood sample with a leukocidal reagent, wherein said reagent substantially inhibits activity of leukocytes in the sample, and wherein the reagent is a mitochondrial electron transport inhibitor, a mitochondrial membrane uncoupling agent, or an amphipathic reagent; and
performing an immunoassay on the sample to detect a target analyte.

### Claim at position 2

2-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the reagent is a mitochondrial electron transport inhibitor.

### Claim 17 (depends on 1)

The method of claim 1, wherein the reagent is a mitochondrial membrane uncoupling agent.

### Claim 18 (depends on 1)

The method of claim 1, wherein the reagent is selected from the group consisting of cyanide, antimycin, rotenone, malonate, carbonyl cyanide p-[trifluoromethoxyl]-phenyl-hydrozone, 2,4-dinitrophenol, and oligomycin.

### Claim 19 (depends on 1)

The method of claim 1, wherein the reagent is an amphipathic reagent.

### Claim 20 (depends on 1)

The method of claim 1, wherein the reagent is saponin.

### Claim 21 (depends on 1)

The method of claim 1, wherein the reagent is a leukocidin.

### Claim 22 (depends on 1)

The method of claim 1, wherein the reagent is a mucopolysaccharide.

### Claim 23 (depends on 1)

The method of claim 1, wherein the reagent is an AHN-1 antibody.

### Claim 24 (depends on 1)

The method of claim 1, wherein the reagent is lipocortin-1.

### Claim 25 (depends on 1)

The method of claim 1, wherein the immunoassay is a sandwich assay performed by contacting the sample with an immunosensor comprising an immobilized first antibody to the target analyte, and a labeled second antibody to the target analyte.

### Claim 26 (depends on 1)

The method of claim 1, wherein the immunoassay is a competitive assay performed by contacting the sample with an immunosensor comprising an immobilized first antibody to the target analyte, and a labeled target analyte.

### Claim 27 (depends on 1)

The method of claim 1, wherein the sample is contacted with beads opsonized for leukocytes.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The method of claim 1, wherein the sample is a whole blood sample.

### Claim 30 (depends on 1)

The method of claim 1, wherein the sample is amended with an anticoagulant.

### Claim 31 (depends on 1)

The method of claim 1, wherein the analyte is selected from the group consisting of TnI, TnT, BNP, NTproBNP, proBNP, HCG, TSH, NGAL, theophylline, digoxin, and phenyloin.

### Claim 32

A kit for performing an immunoassay for a target analyte in a whole blood sample comprising:
a leukocidal reagent wherein said reagent substantially inhibits activity of leukocytes in a sample, and wherein the reagent is a mitochondrial electron transport inhibitor, a mitochondrial membrane uncoupling agent, or an amphipathic reagent, and immunoassay reagents for detecting a target analyte.

### Claim at position 20

33-46. (canceled)

### Claim 47 (depends on 32)

The kit of claim 32, wherein the reagent is a mitochondrial electron transport inhibitor.

### Claim 48 (depends on 32)

The kit of claim 32, wherein the reagent is a mitochondrial membrane uncoupling agent.

### Claim 49 (depends on 32)

The kit of claim 32, wherein the reagent is selected from the group consisting of cyanide, antimycin, rotenone, malonate, carbonyl cyanide p-[trifluoromethoxyl]-phenyl-hydrozone, 2,4-dinitrophenol, and oligomycin.

### Claim 50 (depends on 32)

The kit of claim 32, wherein the reagent is an amphipathic reagent.

### Claim 51 (depends on 32)

The kit of claim 32, wherein the reagent is a saponin.

### Claim 52 (depends on 32)

The kit of claim 32, wherein the reagent is a leukocidin.

### Claim 53 (depends on 32)

The kit of claim 32, wherein the reagent is a mucopolysaccharide.

### Claim 54 (depends on 32)

The kit of claim 32, wherein the reagent is an AHN-1 antibody.

### Claim 55 (depends on 32)

The kit of claim 32, wherein the reagent is lipocortin-1.

### Claim 56 (depends on 32)

The kit of claim 32, wherein the immunoassay is a sandwich assay and wherein the immunoassay reagents comprise an immunosensor comprising an immobilized first antibody to the target analyte, and a labeled second antibody to the target analyte.

### Claim 57 (depends on 32)

The kit of claim 32, wherein the immunoassay is a competitive assay and wherein the immunoassay reagents comprise an immunosensor comprising an immobilized first antibody to the target analyte, and a labeled target analyte.

### Claim 58 (depends on 32)

The kit of claim 32, further comprising beads opsonized for leukocytes.

### Claim 59

(canceled)

### Claim 60 (depends on 32)

The kit of claim 32, wherein the sample is a whole blood sample.

### Claim 61 (depends on 32)

The kit of claim 32, wherein the sample is amended with an anticoagulant.

### Claim 62 (depends on 32)

The kit of claim 32, wherein the analyte is selected from the group consisting of TnI, TnT, BNP, NTproBNP, proBNP, HCG, TSH, NGAL, digoxin, theophylline and phenyloin.
